Generic ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE INN equivalents, drug patent and freedom to operate

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	ATROPINE AND DEMEROL	atropine sulfate; meperidine hydrochloride	INJECTABLE;INJECTION	087853-001	Nov 26, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Wyeth Ayerst	MEPERIDINE AND ATROPINE SULFATE	atropine sulfate; meperidine hydrochloride	INJECTABLE;INJECTION	085121-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Abbvie	ATROPINE AND DEMEROL	atropine sulfate; meperidine hydrochloride	INJECTABLE;INJECTION	087848-001	Nov 26, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: September 5, 2026

Atropine sulfate and meperidine hydrochloride are mature generic medicines with limited patent-driven pricing power. Atropine has a resilient emergency-care market and selective ophthalmic demand, while meperidine hydrochloride has a structurally declining market because of opioid-safety concerns, restricted use, and substitution by morphine, hydromorphone, fentanyl, and other agents. Neither product has a meaningful remaining composition-of-matter exclusivity strategy in the United States. Financial performance depends mainly on manufacturing reliability, hospital contracts, shortage conditions, controlled-substance compliance, and product-specific formulation economics.

What are the primary medical and commercial uses of atropine sulfate and meperidine hydrochloride?

Atropine sulfate is an antimuscarinic drug used in emergency medicine, cardiology, toxicology, anesthesia, and ophthalmology. Meperidine hydrochloride is an opioid analgesic used for short-term treatment of moderate-to-severe pain and, in some settings, for shivering or rigors.

Product	Main dosage forms	Principal uses	Market position
Atropine sulfate	Injectable solution; ophthalmic solution; combination autoinjector products	Symptomatic bradycardia, organophosphate poisoning, preoperative use, pupil dilation and cycloplegia	Stable emergency-care demand; fragmented generic supply
Meperidine hydrochloride	Injection, tablets, oral solution	Short-term acute pain; selected anesthesia and postoperative uses	Declining use because of safety concerns and therapeutic substitution

Atropine is listed in American Heart Association treatment algorithms for selected symptomatic bradycardia cases and remains an established antidote component in organophosphate exposure protocols.[1] Meperidine is a Schedule II controlled substance under the federal Controlled Substances Act.[2]

How large are the markets for atropine sulfate and meperidine hydrochloride?

Public companies generally do not disclose revenue for either molecule separately. Market revenue estimates vary by geography, dosage form, channel, and whether combination products are included. A precise global revenue figure cannot be derived from public company filings alone.

Atropine sulfate market dynamics

Atropine demand is divided between:

Emergency injectable products used by hospitals and emergency medical services.
Ophthalmic products used for pupil dilation and cycloplegic examinations.
Antidote and military or occupational-exposure programs.
Combination products containing atropine and pralidoxime.

The injectable market is relatively defensive. Hospitals must maintain atropine for emergency protocols even when unit volumes are low. This creates baseline demand, but products are usually purchased through group purchasing organizations, hospital systems, distributors, and government procurement contracts. Pricing is therefore competitive when several suppliers are active.

Ophthalmic atropine is more exposed to clinical substitution and product-specific demand. Standard diagnostic concentrations compete with other mydriatic and cycloplegic agents. Low-dose atropine for pediatric myopia control has generated clinical interest, but much of that use is off-label in the United States and does not automatically create a large FDA-approved branded market.[3]

Meperidine hydrochloride market dynamics

Meperidine has a weaker commercial outlook. Its active metabolite, normeperidine, can accumulate and cause neurotoxicity, particularly in patients with renal impairment or prolonged exposure. Clinical guidelines and hospital formularies have therefore reduced its role in routine pain management.[4]

Demand remains in selected acute-care settings, but the market is primarily replacement-driven rather than expansion-driven. Generic meperidine competes with:

Morphine.
Hydromorphone.
Fentanyl.
Oxycodone and other oral opioids for selected indications.
Non-opioid analgesics.
Regional anesthesia and multimodal pain protocols.

The product’s controlled-substance status increases administrative and compliance costs. It also limits inventory flexibility and makes manufacturers and distributors more sensitive to diversion controls, quota management, serialization, and secure handling requirements.

When do atropine sulfate and meperidine hydrochloride lose exclusivity?

Both molecules lost practical market exclusivity many years ago. The relevant commercial question is not the expiration of a single core patent but whether a supplier has an active product-specific patent, regulatory exclusivity, manufacturing advantage, or shortage position.

Exclusivity category	Atropine sulfate	Meperidine hydrochloride
Core composition-of-matter patent	Expired or commercially irrelevant	Expired or commercially irrelevant
New chemical entity exclusivity	None for current generic products	None for current generic products
Typical current competition	Multiple injectable and ophthalmic suppliers	Multiple generic opioid suppliers, with lower demand
Main barrier to entry	Sterile manufacturing, supply reliability, product approval	Controlled-substance compliance, sterile manufacturing, quota and demand constraints
Patent-led price protection	Minimal	Minimal

There is no single commercially meaningful patent-expiration date for either molecule. Approval-specific patents may exist for particular formulations, delivery systems, manufacturing processes, or combination products, but those rights do not restore exclusivity to the underlying active ingredient.

What is the Orange Book status of atropine sulfate and meperidine hydrochloride?

The FDA Orange Book lists approved drug products and, where applicable, patents and regulatory exclusivity.[5] Orange Book status must be reviewed at the individual application and dosage-form level.

For conventional generic atropine sulfate and meperidine hydrochloride products, the commercial pattern is generally:

Abbreviated New Drug Applications rather than new-drug development programs.
No active core patent blocking ordinary generic entry.
Product-specific listing differences among injectable, ophthalmic, oral, and combination formulations.
Potential patent listings for particular delivery systems or novel combinations rather than the old active ingredient itself.

A generic applicant filing an ANDA may use a Paragraph IV certification if it challenges a listed patent. For standard atropine sulfate injection, atropine ophthalmic solution, and meperidine hydrochloride products, Paragraph IV litigation is not the primary market driver because the underlying molecules are long-established and generic competition is already present.

What formulation patents protect atropine sulfate products?

Atropine protection is more likely to attach to the formulation or delivery system than to atropine sulfate itself.

Injectable atropine

The principal barriers are technical and regulatory:

Sterile injectable manufacturing.
Container-closure integrity.
Stability and particulate-control testing.
Accurate low-dose fill and concentration control.
Compatibility with syringes, vials, and emergency kits.
FDA compliance for aseptic processing and quality systems.

These requirements can limit the number of reliable suppliers even when no patent blocks entry. A supplier with validated capacity and a strong hospital distribution network may maintain pricing during a shortage without holding an active patent.

Ophthalmic atropine

Ophthalmic products may have product-specific intellectual-property claims involving:

Preservative systems.
Vehicle composition.
Concentration and pH control.
Unit-dose packaging.
Stability-enhancing excipients.
Specialized delivery systems.

Those claims generally protect a particular product configuration. They do not prevent competitors from selling conventional atropine ophthalmic solutions if the competing product avoids the protected features.

Combination products

Atropine-pralidoxime autoinjectors can have separate device, formulation, and method-of-use considerations. Their commercial profile differs from standalone atropine because procurement may be linked to military, government, emergency-preparedness, or occupational-exposure programs.

What method-of-use patents affect atropine sulfate?

Method-of-use rights are more relevant to new clinical applications than to established emergency uses. Potentially relevant areas include:

Myopia-control regimens using low-dose atropine.
Specific dosing schedules in pediatric ophthalmology.
Combination treatment protocols.
Drug-device administration methods.

In the United States, off-label clinical use does not create product exclusivity by itself. A method-of-use patent can support a labeled indication if the sponsor obtains FDA approval and markets the indication in compliance with applicable patent and labeling rules. However, the existence of clinical interest in low-dose atropine does not establish a durable branded revenue stream.

What patent litigation and Paragraph IV challenges affect these products?

No broad, molecule-level patent litigation currently defines the market for either drug. Litigation risk is more likely to arise from:

A novel atropine ophthalmic formulation.
A proprietary delivery device.
A combination product.
A process patent tied to a specific manufacturing method.
A branded reformulation seeking commercial differentiation.

For meperidine, patent litigation is commercially less likely because demand is declining and the market does not generally support expensive lifecycle-management programs. A Paragraph IV challenge to a new meperidine formulation would need sufficient expected revenue to justify litigation and launch costs, which is difficult in a shrinking opioid market.

How does FDA regulatory status affect the financial outlook?

Both products are FDA-approved prescription medicines, but their regulatory economics differ.

Atropine sulfate

FDA-approved atropine products benefit from essential-use demand in emergency medicine. FDA drug-shortage monitoring is commercially important because sterile injectable supply interruptions can change hospital purchasing behavior and improve short-term pricing for available suppliers.[6]

The principal risks are:

Manufacturing-site interruptions.
Raw-material shortages.
Inspection findings.
Sterility failures.
Concentration or labeling errors.
Withdrawal of a low-volume supplier.

Because emergency injectable products are often low-price generics, profitability can deteriorate quickly if a manufacturer experiences a quality event or loses production yield.

Meperidine hydrochloride

Meperidine carries a boxed warning for risks associated with opioid use, including addiction, abuse, misuse, life-threatening respiratory depression, and interaction with monoamine oxidase inhibitors. The labeling also addresses normeperidine-associated seizure risk and the need to limit treatment duration.[7]

These restrictions reduce prescribing and make formulary adoption more difficult. FDA approval remains intact, but approval does not imply favorable volume growth. The financial trajectory is constrained by clinical de-adoption rather than regulatory exclusivity.

How strong is the patent estate for atropine sulfate compared with meperidine hydrochloride?

Attribute	Atropine sulfate	Meperidine hydrochloride
Core patent strength	Very low	Very low
Formulation opportunity	Moderate in ophthalmic and device products	Low
Method-of-use opportunity	Selective, particularly ophthalmic uses	Very limited
Regulatory barrier	Moderate for sterile injectables	Moderate to high because of controlled-substance requirements
Demand outlook	Stable in emergency care; selective growth in ophthalmics	Declining
Pricing power	Episodic and supply-dependent	Weak
Litigation attractiveness	Possible for differentiated ophthalmic products	Low

Atropine has the stronger commercial platform because it supports multiple clinical applications and emergency procurement. Meperidine has greater compliance friction but less strategic value for lifecycle investment.

Which companies are challenging the market, and what is the competitive landscape?

The competitive landscape is fragmented across generic manufacturers, specialty injectable companies, ophthalmic suppliers, contract manufacturers, and hospital distributors. Product-specific sponsor rosters change as applications are transferred, discontinued, or acquired.

Competition is based on:

FDA-approved presentation and concentration.
Sterile manufacturing capacity.
Back-order performance.
Contract pricing.
Hospital and distributor relationships.
Ability to maintain controlled-substance records for meperidine.
Packaging suitability for emergency departments and operating rooms.

Large diversified generic companies can tolerate low unit prices better than small suppliers, but they may also exit low-margin products if manufacturing complexity is high. Smaller specialty manufacturers can gain share during shortages but face greater dependence on individual plants, customers, or contracts.

What licensing deals affect atropine sulfate and meperidine hydrochloride?

No major publicly disclosed licensing transaction is required to explain the current market position of conventional atropine sulfate or meperidine hydrochloride. These products are mature generics, and commercial arrangements are more likely to involve:

Contract manufacturing.
Product distribution.
ANDA transfers.
Hospital supply agreements.
Government procurement contracts.
Private-label arrangements.

Licensing value is more plausible for a differentiated atropine delivery device, combination antidote, or ophthalmic formulation than for standard meperidine or conventional atropine injection.

What is the likely financial trajectory for each drug?

Atropine sulfate: stable base with episodic upside

Atropine revenue is likely to remain stable in established emergency-care channels. Growth depends on:

Expansion of hospital and emergency-medical-service capacity.
Government stockpiling and preparedness programs.
Ophthalmic product innovation.
Low-dose atropine adoption if regulatory and reimbursement pathways improve.
Supply disruptions affecting competing injectable products.

The product is unlikely to produce high branded-drug margins without a differentiated formulation, device, or protected indication. The strongest financial opportunity lies in reliable sterile supply, differentiated packaging, and specialty ophthalmic products.

Meperidine hydrochloride: declining volume with occasional supply-driven pricing

Meperidine has a negative underlying demand trend. Revenue can remain viable for a supplier with low-cost manufacturing, but long-term volume expansion is unlikely. Short-term financial improvements may occur during competitor exits or shortages, but those gains are not equivalent to durable market growth.

The principal downside factors are:

Continued opioid stewardship.
Hospital substitution with safer or more familiar analgesics.
Low prescribing in older and renal-impaired patients.
Controlled-substance compliance costs.
Reduced formulary preference.
Limited rationale for new clinical investment.

What generic launch scenarios exist?

Scenario	Atropine sulfate	Meperidine hydrochloride
New conventional generic entrant	Possible where supply is limited; price erosion likely	Possible but limited by small and declining demand
Supplier exit	Can create shortage-driven price increases	Can create temporary supply pressure but may not restore demand
New formulation launch	Commercially credible in ophthalmics or devices	Economically difficult
Branded lifecycle product	Possible around delivery or indication	Unlikely
Biosimilar entry	Not applicable	Not applicable

Neither molecule is a biologic, so biosimilar risk does not apply. The relevant competitive threat is conventional generic substitution.

How much revenue exposure do manufacturers face?

Revenue concentration is product-specific. For large pharmaceutical companies, standalone atropine and meperidine sales are generally unlikely to represent a material share of consolidated revenue. Exposure can still be significant for:

Small injectable-generic companies.
Specialty ophthalmic manufacturers.
Government-contract suppliers.
Companies dependent on a single sterile manufacturing site.
Distributors holding controlled-substance inventory.

Atropine has higher strategic value because it can anchor an emergency-injectables portfolio. Meperidine is more likely to be retained as part of a broader opioid catalog than as a growth product.

What geographic markets matter most?

The United States is commercially important because of its large hospital market, FDA shortage reporting, GPO contracting, and controlled-substance regulation. Europe and other developed markets also use atropine and meperidine, but product names, concentrations, reimbursement, procurement systems, and opioid prescribing practices differ.

Geographic expansion is constrained by:

Country-specific approvals.
Sterile manufacturing requirements.
Controlled-substance import and distribution rules.
Local pharmacopoeia standards.
Reimbursement prices.
Government tender competition.

Atropine has broader international utility because of its emergency and toxicology roles. Meperidine demand varies more sharply by national prescribing norms.

Key Takeaways

Atropine sulfate is a mature generic with resilient emergency-care demand and selective ophthalmic growth potential.
Meperidine hydrochloride is a mature Schedule II opioid with declining use and weak long-term growth prospects.
Neither molecule has meaningful remaining core-patent exclusivity.
Atropine formulation, device, and method-of-use patents can support differentiated products, especially in ophthalmology.
Meperidine’s principal barriers are controlled-substance compliance and manufacturing economics, not intellectual property.
Paragraph IV litigation is not the central market risk for conventional products.
Atropine financial performance is driven by sterile-supply reliability, hospital contracting, and shortage conditions.
Meperidine financial performance is driven by supplier exits, controlled-substance operations, and residual institutional demand.
Biosimilar competition is irrelevant because both products are small-molecule drugs.
The strongest commercial opportunity is differentiated atropine delivery or ophthalmic development, not meperidine lifecycle expansion.

FAQs

Is atropine sulfate still a profitable generic drug?

It can be profitable for suppliers with efficient sterile manufacturing, reliable supply, and hospital contracts. Conventional products have limited pricing power, so profitability depends on production cost and supply availability.

Is meperidine hydrochloride being discontinued?

Meperidine remains an FDA-approved opioid product, but many hospitals have reduced or eliminated routine use. Market withdrawal by an individual manufacturer does not necessarily mean that all meperidine products are discontinued.

Does atropine sulfate have Orange Book patents?

Some product applications may contain formulation, device, or use-related listings, but standard atropine sulfate products do not rely on an active core patent to exclude generic competitors.

Can low-dose atropine for myopia control create new market exclusivity?

Potentially, if a sponsor obtains an approved indication and secures valid method-of-use or formulation claims. Off-label use alone does not create FDA regulatory exclusivity.

Are meperidine products subject to biosimilar competition?

No. Meperidine is a small-molecule drug. Competition comes from generic manufacturers and therapeutic alternatives such as morphine, hydromorphone, and fentanyl.

References

American Heart Association. (2020). 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation, 142(Suppl. 2).
U.S. Drug Enforcement Administration. (n.d.). Drug scheduling. https://www.dea.gov/drug-information/drug-scheduling
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
Chou, R., Gordon, D. B., de Leon-Casasola, O. A., et al. (2016). Management of postoperative pain: A clinical practice guideline. The Journal of Pain, 17(2), 131-157.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
U.S. Food and Drug Administration. (n.d.). Drug shortages. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages
U.S. Food and Drug Administration. (n.d.). Demerol and meperidine hydrochloride prescribing information. FDA-approved product labeling.

US Patents:	0
Tradenames:	2
Applicants:	2
NDAs:	4
DailyMed Link:	ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE at DailyMed

ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE - Generic Drug Details

What are the generic sources for atropine sulfate; meperidine hydrochloride and what is the scope of freedom to operate?

Summary for ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

Anatomical Therapeutic Chemical (ATC) Classes for ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

US Patents and Regulatory Information for ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

Atropine Sulfate and Meperidine Hydrochloride Market Dynamics, Patent Status, and Financial Trajectory